Direct oral anticoagulants are preferred in chronic kidney disease stages 1-4, while apixaban and rivaroxaban demonstrate comparable efficacy to warfarin in end-stage renal disease.
What are the optimal anticoagulation strategies for patients with atrial fibrillation and chronic kidney disease?
This review highlights that direct oral anticoagulants are preferred in mild-to-moderate CKD, while apixaban and rivaroxaban offer comparable efficacy to warfarin in end-stage renal disease.
Absolute Event Rate: 0% vs 0%
Atrial fibrillation and chronic kidney disease (CKD) frequently coexist, increasing thromboembolic and bleeding risks. This is a narrative review of pathophysiology and clinical evidence for anticoagulation strategies in CKD patients. Direct oral anticoagulants are preferred in CKD stages 1-4. Recent data suggest that the efficacy of apixaban and rivaroxaban is comparable to that of warfarin in end-stage renal disease. In advanced CKD, anticoagulation should be tailored with close monitoring.
L et al. (Sun,) reported a other. Direct oral anticoagulants are preferred in chronic kidney disease stages 1-4, while apixaban and rivaroxaban demonstrate comparable efficacy to warfarin in end-stage renal disease.